Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.

Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ.

Antimicrob Agents Chemother. 2005 Jun;49(6):2267-75.

2.

Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK.

Antimicrob Agents Chemother. 2005 Feb;49(2):619-26.

3.

An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents.

Ettinger A, Ostroff R, Rhihanek M, Dragovich PS, Zalman LS, Patick AK, Prins TJ, Fuhrman SA, Brown EL, Worland ST, Polisky B.

Antiviral Res. 2004 Mar;61(3):153-9.

PMID:
15168795
4.

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.

Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ 3rd, Zalman LS.

Antimicrob Agents Chemother. 2003 Dec;47(12):3907-16.

5.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA.

J Med Chem. 2003 Oct 9;46(21):4572-85.

PMID:
14521419
6.

Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS.

J Med Chem. 2002 May 9;45(10):2016-23.

PMID:
11985469
7.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 2002 Apr 11;45(8):1607-23.

PMID:
11931615
8.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8.

PMID:
11858991
9.

Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Zalman LS, Brothers MA, Dragovich PS, Zhou R, Prins TJ, Worland ST, Patick AK.

Antimicrob Agents Chemother. 2000 May;44(5):1236-41.

10.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW 3rd, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):45-8.

PMID:
10636240
11.

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST.

Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50.

12.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7.

13.

Comparison of human cytomegalovirus (HCMV) protease sequences among laboratory strains and seven clinical isolates.

Huffaker TK, Binford S, Patick AK, Pinko C, Kan CC, Zalman LS.

Antiviral Res. 1997 Feb;33(3):215-8.

PMID:
9037377
14.

Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.

Zalman LS, Müller-Eberhard H.

Mol Immunol. 1994 Mar;31(4):301-5.

PMID:
8139583
15.

Homologous restriction factor.

Zalman LS.

Curr Top Microbiol Immunol. 1992;178:87-99. Review. No abstract available.

PMID:
1424777
16.

Inhibition of cytolytic lymphocytes by homologous restriction factor. Lack of species restriction.

Zalman LS, Brothers MA, Strauss KL.

J Immunol. 1991 Jun 15;146(12):4278-81.

PMID:
1904077
17.

Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement.

Zalman LS, Müller-Eberhard HJ.

Mol Immunol. 1990 Jun;27(6):533-7.

PMID:
1696352
18.

Isolation of homologous restriction factor from human urine. Immunochemical properties and biologic activity.

Zalman LS, Brothers MA, Müller-Eberhard HJ.

J Immunol. 1989 Sep 15;143(6):1943-7.

PMID:
2476489
19.

Self-protection of cytotoxic lymphocytes: a soluble form of homologous restriction factor in cytoplasmic granules.

Zalman LS, Brothers MA, Müller-Eberhard HJ.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4827-31.

20.
21.

Expression and modulation of homologous restriction factor (HRF) on peripheral white blood cells.

Sayama K, Zalman LS, Müller-Eberhard HJ, Gigli I.

Trans Assoc Am Physicians. 1988;101:270-81. No abstract available.

PMID:
2855898
22.
23.

Molecular mechanisms of cytotoxicity: comparison of complement and killer lymphocytes.

Müller-Eberhard HJ, Zalman LS, Chiu FJ, Jung G, Martin DE.

J Rheumatol Suppl. 1987 Jun;14 Suppl 13:28-34.

PMID:
3612651
25.
26.

Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.

Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ.

J Exp Med. 1987 Feb 1;165(2):572-7.

27.
28.
29.

Characterization of the insertion of Pseudomonas exotoxin A into membranes.

Zalman LS, Wisnieski BJ.

Infect Immun. 1985 Dec;50(3):630-5.

30.

A C9 related channel forming protein in the cytoplasmic granules of human large granular lymphocytes.

Zalman LS, Brothers MA, Müller-Eberhard HJ.

Biosci Rep. 1985 Dec;5(12):1093-100.

PMID:
3830274
31.

Dimeric porin from Paracoccus denitrificans.

Zalman LS, Nikaido H.

J Bacteriol. 1985 Apr;162(1):430-3.

32.

Porin from Rhodopseudomonas sphaeroides.

Weckesser J, Zalman LS, Nikaido H.

J Bacteriol. 1984 Jul;159(1):199-205.

33.

Mechanism of insertion of diphtheria toxin: peptide entry and pore size determinations.

Zalman LS, Wisnieski BJ.

Proc Natl Acad Sci U S A. 1984 Jun;81(11):3341-5.

34.

Purification and properties of Pseudomonas aeruginosa porin.

Yoshimura F, Zalman LS, Nikaido H.

J Biol Chem. 1983 Feb 25;258(4):2308-14. No abstract available.

35.

Mitochondrial outer membrane contains a protein producing nonspecific diffusion channels.

Zalman LS, Nikaido H, Kagawa Y.

J Biol Chem. 1980 Mar 10;255(5):1771-4.

Supplemental Content

Loading ...
Support Center